ADGRD1 and glioblastoma: As we validated selective expression of GPR133 in hypoxic regions of GBM with additional immunostaining using a mouse monoclonal anti-GPR133 antibody, we developed against the extracellular pentraxin/concanavalin A domain (Supplementary Figure 4a).